Author

Jo Ingham

Observed names: J Ingham, J. Ingham

Observed institutions: University of Siena, York Hospital, University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital Birmingham, Southampton General Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Karolinska Institutet, Manchester University NHS Foundation Trust, The Christie Hospital, The Christie NHS Foundation Trust, Centre for Inflammation Research, University of Birmingham, Newcastle University, University of Edinburgh

OpenAlex ID: A5055949207

Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study

2022 · R A Evans, O C Leavy, et al. · The Lancet Respiratory Medicine · 413

PDF

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis

2022 · Obbina Abani, Ali Abbas, et al. · The Lancet · 324

GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19

2023 · Erola Pairo-Castineira, Konrad Rawlik, et al. · Nature · 224

PDF

Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial

2023 · Obbina Abani, Ali Abbas, et al. · The Lancet · 129

SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination

2022 · Felicity Liew, Shubha Talwar, et al. · EBioMedicine · 121

A second update on mapping the human genetic architecture of COVID-19

2023 · The COVID-19 Host Genetics Initiative, Leadership, et al. · Nature · 118

PDF

Landiolol and Organ Failure in Patients With Septic Shock

2023 · Tony Whitehouse, Anower Hossain, et al. · JAMA · 107

Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial

2024 · Chris C Parker, Noel W Clarke, et al. · The Lancet · 53

Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

2023 · O Abani, A Abbas, et al. · The Lancet Diabetes & Endocrinology · 41

PDF

Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial

2024 · Saul N Faust, Richard Haynes, et al. · The Lancet Child & Adolescent Health · 39

PDF

Common, low-frequency, rare, and ultra-rare coding variants contribute to COVID-19 severity

2021 · Chiara Fallerini, Nicola Picchiotti, et al. · Human Genetics · 37

PDF

Effects of sleep disturbance on dyspnoea and impaired lung function following hospital admission due to COVID-19 in the UK: a prospective multicentre cohort study

2023 · Callum Jackson, Iain D Stewart, et al. · The Lancet Respiratory Medicine · 35

Accelerated immune ageing is associated with COVID-19 disease severity

2024 · Janet M. Lord, Tonny Veenith, et al. · Immunity & Ageing · 34

PDF

Determinants of recovery from post-COVID-19 dyspnoea: analysis of UK prospective cohorts of hospitalised COVID-19 patients and community-based controls

2023 · Bang Zheng, Giulia Vivaldi, et al. · The Lancet Regional Health - Europe · 29

Prevalence of physical frailty, including risk factors, up to 1 year after hospitalisation for COVID-19 in the UK: a multicentre, longitudinal cohort study

2023 · Hamish J.C. McAuley, Rachael A. Evans, et al. · EClinicalMedicine · 24

PDF

Cohort Profile: Post-Hospitalisation COVID-19 (PHOSP-COVID) study

2023 · Omer Elneima, Hamish J C McAuley, et al. · International Journal of Epidemiology · 23

PDF

Post-acute COVID-19 neuropsychiatric symptoms are not associated with ongoing nervous system injury

2023 · Maxime Taquet, Zuzanna Skorniewska, et al. · Brain Communications · 14

PDF

Molnupiravir or nirmatrelvir–ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

2025 · O Abani, A Abbas, et al. · The Lancet Infectious Diseases · 12

PDF

Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

2024 · RECOVERY Collaborative Group, Peter Sandercock, et al. · Nature Communications · 11

PDF

Long COVID research: an update from the PHOSP-COVID Scientific Summit

2023 · Christopher E Brightling, Rachael A Evans, et al. · The Lancet Respiratory Medicine · 11

PDF

Author Correction: GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19

2023 · Erola Pairo-Castineira, Konrad Rawlik, et al. · Nature · 9

PDF

Plasma AR Alterations and Timing of Intensified Hormone Treatment for Prostate Cancer

2025 · Gianmarco Leone, Francesco Orlando, et al. · JAMA Oncology · 5

Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial

2025 · O. Abani, A. Abbas, et al. · EClinicalMedicine · 5

WILL (When to Induce Labour to Limit risk in pregnancy hypertension): a multicentre randomised controlled trial — adaptations to deliver a timing-of-birth trial during the COVID-19 international pandemic

2022 · Laura A. Magee, Sue Tohill, et al. · Trials · 5

PDF

The effects of ultra-selective beta1-antagonism on the metabolic and cytokine profile in septic shock patients receiving noradrenaline: a sub-investigation from the STRESS-L Randomised Study

2025 · Jarrod L. Thomas, Kirsty C. McGee, et al. · Intensive Care Medicine Experimental · 4

PDF

Works count: 29

Citation count: 1,884

H-index: 17

I10-index: 22